Literature DB >> 12144829

Treatment preferences in recurrent ovarian cancer.

Kristine A Donovan1, Paul G Greene, John L Shuster, Edward E Partridge, Diane C Tucker.   

Abstract

OBJECTIVES: In the case of recurrent ovarian cancer, salvage therapy represents the potential to trade off between quality and quantity of life. Patient and physician face a choice between chemotherapy directed at slowing disease progression and supportive or palliative care that focuses on symptom management. To date, no studies have investigated the effects of best supportive care on ovarian cancer patients' quality of life and length of life as compared to salvage therapy. In other cancers, both quantity and quality of life considerations have been shown to affect treatment preferences.
METHODS: Using a decision board, we assessed preferences for salvage therapy or palliative care in the case of recurrent ovarian cancer among 81 ovarian cancer patients receiving first-line chemotherapy and 75 Noncancer Controls.
RESULTS: Compared to Noncancer Controls, ovarian cancer patients overwhelmingly preferred salvage therapy; quantity of life was of primary importance. In both groups, preference was not related to age, marital status, number of children, or employment status. On average, patients indicated they would switch from salvage therapy to palliative care when the median survival associated with salvage therapy was reduced to 5 months. Noncancer Controls would switch significantly sooner, when the median increment in survival period was reduced to 8 months. Switchpoint was not associated with life satisfaction, quality of life, or psychological or spiritual well-being in either group.
CONCLUSIONS: The majority of women, independent of a cancer diagnosis, indicated a desire for continuing aggressive treatment, despite poor outcomes. Quality of life was of secondary importance, especially among ovarian cancer patients.

Entities:  

Mesh:

Year:  2002        PMID: 12144829     DOI: 10.1006/gyno.2002.6748

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  26 in total

1.  Prospective study of health status preferences and changes in preferences over time in older adults.

Authors:  Terri R Fried; Amy L Byers; William T Gallo; Peter H Van Ness; Virginia R Towle; John R O'Leary; Joel A Dubin
Journal:  Arch Intern Med       Date:  2006-04-24

2.  The Experience of Being Aware of Disease Status in Women with Recurrent Ovarian Cancer: A Phenomenological Study.

Authors:  Catherine Scott Finlayson; Mei R Fu; Allison Squires; Allison Applebaum; Janet Van Cleave; Roisin O'Cearbhaill; Antonio P DeRosa
Journal:  J Palliat Med       Date:  2018-11-08       Impact factor: 2.947

3.  Refining a Web-based goal assessment interview: item reduction based on reliability and predictive validity.

Authors:  Carolyn E Schwartz; Jei Li; Bruce D Rapkin
Journal:  Qual Life Res       Date:  2016-03-10       Impact factor: 4.147

4.  Effect of endurance for adverse drug reactions on the preference for aggressive treatments in cancer patients.

Authors:  Naomi Iihara; Takayuki Nishio; Tetsuko Goda; Hideaki Anzai; Masatoshi Kagawa; Hitoshi Houchi; Yutaka Kirino
Journal:  Support Care Cancer       Date:  2014-10-08       Impact factor: 3.603

5.  Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients.

Authors:  Vanessa L Beesley; Alexandra M Clavarino; Penelope M Webb; David K Wyld; Alessandra B Francesconi; Keith R Horwood; James D Doecke; Colleen A Loos; Adele C Green
Journal:  Support Care Cancer       Date:  2009-09-24       Impact factor: 3.603

6.  Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment.

Authors:  Laura J Havrilesky; Gloria Broadwater; Debra M Davis; Kimberly C Nolte; J Cory Barnett; Evan R Myers; Shalini Kulasingam
Journal:  Gynecol Oncol       Date:  2009-02-12       Impact factor: 5.482

7.  Palliative Chemotherapy Affects Aggressiveness of End-of-Life Care.

Authors:  Chin-Chia Wu; Ta-Wen Hsu; Chun-Ming Chang; Cheng-Hung Lee; Chih-Yuan Huang; Ching-Chih Lee
Journal:  Oncologist       Date:  2016-04-18

Review 8.  Quality-of-life issues in the management of epithelial ovarian cancer.

Authors:  Thomas Lowe; Betty Ferrell; Lucille Leong
Journal:  Curr Treat Options Oncol       Date:  2007-12

9.  Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.

Authors:  Shin Nishio; Noriyuki Katsumata; Koji Matsumoto; Hiroshi Tanabe; Kan Yonemori; Tsutomu Kouno; Chikako Shimizu; Masashi Ando; Toshiharu Kamura; Takahiro Kasamatsu; Yasuhiro Fujiwara
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-01       Impact factor: 4.553

10.  Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Vivian E von Gruenigen; Helen Q Huang; David Cella; MichaelA Zevon; Jason A LaChance; Joan L Walker; Ritu Salani; Susan C Modesitt; Robert T Morris; William H Bradley; Matthew P Boente; Lari Wenzel
Journal:  Gynecol Oncol       Date:  2018-05-18       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.